Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is indicated for adults with type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise. It is also indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
How much does Tirzepatide cost?
The list price for Tirzepatide (Mounjaro) varies based on dosage and quantity. For example, a 10 mg/0.5 mL pen has a list price of approximately $994.11 for a 4-week supply. A 15 mg/0.5 mL pen has a similar list price of approximately $994.11 for a 4-week supply. For Zepbound, the list price for a 5 mg/0.5 mL pen is approximately $994.11 for a 4-week supply [1].
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound are both brand names for tirzepatide. Mounjaro is FDA-approved for improving glycemic control in adults with type 2 diabetes and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Zepbound is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity [1].
When does Tirzepatide's patent expire?
Patent information for Tirzepatide is complex and involves multiple patents covering various aspects of the drug, including its composition of matter, methods of use, and manufacturing. DrugPatentWatch.com tracks these patents. For instance, a composition of matter patent for tirzepatide had an original expiry date in 2036, but patent term extensions and other patents can affect the actual market exclusivity dates [2].
What are the alternatives to Tirzepatide for type 2 diabetes?
For type 2 diabetes, alternatives to tirzepatide include other classes of medications such as metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and other GLP-1 receptor agonists. The choice of medication depends on individual patient factors, including efficacy, side effects, cost, and comorbidities.
What are the alternatives to Tirzepatide for weight management?
For chronic weight management, alternatives to tirzepatide include other FDA-approved weight loss medications, lifestyle interventions involving diet and exercise, and bariatric surgery. Other medications may include semaglutide (Wegovy), liraglutide (Saxenda), phentermine-topiramate (Qsymia), and naltrexone-bupropion (Contrave).
What clinical trials have been conducted for Tirzepatide?
Tirzepatide has been studied in several clinical trials, including the SURMOUNT program for obesity and the SURPASS program for type 2 diabetes. These trials have evaluated its efficacy and safety in various patient populations and compared it against placebo and other active treatments. The results have demonstrated significant improvements in glycemic control and body weight reduction [1].
What are the potential side effects of Tirzepatide?
Common side effects of tirzepatide include nausea, vomiting, diarrhea, decreased appetite, constipation, and abdominal pain. More serious but less common side effects can include pancreatitis, gallbladder problems, kidney problems, and severe allergic reactions. Patients are advised to discuss potential risks and benefits with their healthcare provider [1].